Member Info for chester18

WeTookPelham

Let's wait and see how the AGM unfolds.

It's getting awful close to a point where Bristol Myers Squibb are compelled to make Scancell an Offer or broker a deal for a Worldwide Development and Distribution Partnership.

Once this has been achieved :

" The SCOPE trial has now successfully transitioned into the second stage, which will recruit a further 27 patients (for a total of 43). The aim is to achieve at least 18 further responses (i.e., 27 responses in total) which would statistically demonstrate that SCIB1, in combination with doublet therapy, exceeds currently achievable ORRs".

LD will be fending of any Derisory Offers.

Chester.

C11

I totally agree but also want MHRA to only proceed when they are convinced the additional epitopes and the inclusion of AvidiMab are safe.

ISCIB+ is oncology technology that is so new that safety 'belts and braces' are necessary.

As already mentioned, once approval is given it will not take long to enroll the required number of patients. The current Scope Trail is restricted to around 30% of Melanoma suffers. The news of how well SCIB1 + the CPI'S is doing will be known to all the cancer clinicians involved in oncology / Immunology.

If we were ever concerned that we hadn't backed a winner in Scancell, well now we know we have. It's just a matter of time and the positive data will arrived.

Chester.

A genuinely fantastic RNS, not only the increase to 85% but a patient with a clear scan.

In a late stage aggressive desiese these are outstanding outcomes.

If Modi1 plus CPI's match these results there will surely be a bid for the company. There are a half dozen or more Large Pharma Co's that would love to these platforms in-house.

Excellent news for us and cancer patients.

Chester.

From the Reneuron RNS 8th November,

'The Group ended the period to 30 September 2023 with cash, cash equivalents and bank deposits of £5.1 million with the cash runway being extended into the start of calendar Q2 2024.'

No mention of Q125.

Year dates all wrong.

"As of 30 September 2023, Reneuron had cash balance of £5.1m, which we estimate should fund operations into 'Q125', consistent with management's expected cash runway to April 2024" ????

More errors in the Full Report.

Technology making the world dumber.

EE,

That would be an early Christmas Present 😅 👍🤞 🙏

Chester.

Only things that have been RNS'd to the market can be discussed at the AGM. What can be projected either via the presentation or the Q&A section, is how things are progressing especially the Trials and potential discussions becoming Deals.

There is time yet to have an RNS land.

For instance, it would be nice to hear if iSCIB+ is close to approval.

Chester.

Hi Phil

From : PharmaWeb.com

'What is the market for exosome diagnostics and therapeutics?'

According to the report, the global exosome diagnostic and therapeutic industry was estimated at $224.34 million in 2020, and is anticipated to hit $2.9 billion by 2030, registering a CAGR of 29.4% from 2021 to 2030.

So it shows that there is definitely a growing market for a Fully Working Exosome Platform.

Chester.

The attraction of this share is the potential upside if any positive news does land.

What we do know is that Exosomes have the potential to improve the targeted delivery of some drugs that lack the precision to find their designated human cells.

We also know that some fairly sizeable deals have already been made and Exosomes that achieve their potential will be worth £10M's.

Reneuron may have just proved that their Exosomes are some of the best in class.

Obviously proved in their own labs but interested parties must be examining the data.

My opinion is that they have better than a 50/50 chance to do a deal before next February/ March.

Added to these assumptions is that the market Capitalisation is so low that the Assets, Patents and Intellectual Property are probably worth much more.

Chester18.

FAO Burble,

Hi Burble did you see my post re: the answer from Scancell ?

Does it answer your questions as to how the two charts differ ?

Chester.

"Inflamed Adrenal Glands" near to the kidneys, does not sound like a Immunobody side affect. I may be wrong but I don't think SCIB1 causes that kind of off-target toxicity.

Also, there is no mention of CPI's so it cannot be that part of our trial.

Only my opinion from what we have been told in the past.

Chester.

That is a chunky purchase and goes directly against the current sentiment of selling off RENE.

It is such a large and positive statement that I'm wondering if we'll see more of the same tomorrow.

Chester.

FAO Burble,

Hi Burble did you see my post at 13.07 Yesterday ?

Does it answer your questions as to how the two charts differ ?

Chester.

Subject: Re: SCIB1 Charts September/ November

To Burble et al:

Answer from Scancell regarding the difference in the two Swimmer Line Charts as presented as Abstracts at a conference in September and the one presented on the 9th November.

"We have two cohorts in the SCOPE study one is SCIB1 with @CTLA4 and @PD1 and this is the cohort that have an 82% response rate and are doing amazingly well. The second cohort is SCIB1 with just @PD1. This cohort has a 67% response rate but is difficult to recruit too as most patients get the double checkpoints. We only have three patients in this cohort. The poster reflects both groups and the abstracts are submitted well before the meetings. The SMR meeting was a late breaking session so the abstracts were submitted nearer the meeting although the meeting was after the CIMT meeting. So the simple answer is timing and cohorts but the bottom line is the double checkpoint group plus SCIB1 is doing very well".

kind regards,

Prof Lindy Durrant

CEO

Chester.

Hi KonarA

That is was happened at last year's AGM.

Chester.

Morning Burble

This mornings RNS states that another Abstract Poster will be on the Website shortly. Let's wait for that one and compare again.

Definitely worth a question at the AGM.

Chester.

Did Present, yesterday!!

Unusual to be told after the event.

It does show a determination to let the wider Oncology market know that this is a game changing combination with CPI's for Melanoma cancer.

Chester.

There have been some decent deals for Exosomes, so there must be a concensus that exosomes are a worthy pursuit.

If exosomes are the carrier and drug delivery mule of the future, Reneuron's CustomEX platform will be worth at least the current MCap. 😄

Are they going to achieve a deal with some upfront cash is the question, and it's needed inside 3 months.

I think it's been said a few times, this is now a binary play. If there is a company out there that sees Rene's Exosomes as the best possible fit the reward could be worth waiting for.

I'm not holding a huge number of shares but I'm going to stay invested as there are some signs of possible green shoots.

Good luck to all.

Chester.

There are a few posters on this board that will understand the technical stuff better than myself but, the Abstract shouts that these are 'ground breaking' results for the eligible Melanoma cancer sufferers.

I akso picked up on the use of 'Trailblazing' in the summing up.

The next big news will be iSCIB+ being approved for trial inclusion. The same 82% across all Melanoma patients would get the attention of the whole oncology market.

Chester.

The Abstract is now on the Scancell website under Vaccine Publications.

Chester.